Cangene Corporation

Cangene Corporation engages in the development, manufacture, and commercialization of hyperimmune and recombinant biopharmaceuticals in Canada, Eurasia, and the United States. It develops hyperimmunes, which are concentrated specialty antibody preparations made from plasma, and recombinant biopharmaceuticals that are therapeutic proteins made by introducing a particular gene into a host organism, which in turn produces the protein of interest. Its products include WinRHO SDF to prevent hemolytic disease of the newborn and to treat immune thrombocytopenic purpura, as well as to treat platelet drop in dengue hemorrhagic fever or related to hepatitis C treatment; VariZIG for the prevention of chickenpox during pregnancy; and HepaGam B for the treatment following hepatitis B exposure and following liver transplantation in hepatitis-B positive patients. The company’s products also comprise Vaccinia Immune Globulin to treat severe reactions that accompany smallpox vaccinations; Botulism antitoxin for the treatment of botulism; Anthrax immune globulin to treat inhalational anthrax; Ricin immune globulin for the treatment of ricin poisoning. In addition, Cangene Corporation provides Ebola/Marburg antibodies for the prevention and treatment of hemorrhagic fever caused by Ebola or Marburg viruses; Leucotropin to enhance mature white-blood-cell production in stem cell transplantation for cancer patients; PEG-Leucotropin to treat acute radiation syndrome; Accretropin, which normalizes growth in children with growth hormone deficiency and girls with Turner syndrome; and PEP 35 for inhibiting post-surgical infection by antibiotic resistant Staphylococcus aureus bacteria. Further, it offers contract manufacturing services, including process development, bulk product manufacturing, and finished product manufacturing services to other organizations. The company was founded in 1984 and is headquartered in Winnipeg, Canada.